News – Page 1099 – Endpoints News

Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb

8 years ago

Trading places with Bristol-Myers, Merck hit with another late-stage setback on checkpoint star Keytruda

8 years ago

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta

8 years ago

Troubled Teva brings out the ax as it cuts deep into its Israeli pharma group

8 years ago

Gilead details its case for a new HIV flagship triple, with megablockbuster potential

8 years ago

Another micro-cap biotech has flunked a pivotal test for a regenerative cell therapy

8 years ago

Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as PhII cancer trial looms

8 years ago

Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar

8 years ago

Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson’s program for $1.1B

8 years ago

Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug

8 years ago

An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

8 years ago

Takeda explores computational chemistry leads from Schrödinger in $170M-plus pact; Aeterna Zentaris boots CEO, ...

8 years ago

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall

8 years ago

Peer Review: GSK recruits a star cancer scientist to its board ahead of R&D reorganization

8 years ago

Mission possible: AstraZeneca CEO Soriot rallies the troops, promising to fight on

8 years ago

Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK

8 years ago

Trevi gets $50M and David Meeker as its new chairman; Spark in line for a PRV

8 years ago

Langer-backed Kala scores $90M IPO as it lines up a pair of NDAs

8 years ago

Heartburn: Ironwood shares sink after blockbuster contender disappoints on a key goal in PhIIb

8 years ago

What's holding back biotech M&A? SVB tracks a trend and calls a comeback

8 years ago

With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round

8 years ago

Roche punts a PhI cancer drug out of the pipeline and back to Oryzon

8 years ago

Spurned by AbbVie, Ablynx wins another Big Pharma partner offering a blockbuster prize for success

8 years ago

European watchdog wants to manage “risks” of early contacts between regulators, biopharma

8 years ago

First page Previous page 1096 1097 109810991100 1101 1102 Next page Last page